Case Study: Immunomodulatory Mechanism and Antimyeloma Effect of Daratumumab

Description

Patients with multiple myeloma and plasma cell leukemia (PCL) transformation tend to have a poor prognosis due to a high level of resistance to conventional therapy. A recent case study, presented by Yu Wu, MD, PhD, and colleagues of the Sichuan University in Chengdu, China, featured a 42-year-old man with resistant multiple myeloma who had PCL transformation and was successfully treated with daratumumab. The patient experienced complete remission followed by autologous hematopoietic stem cell transplantation (auto-HSCT). The details of this case presentation were published in Therapeutic Advances in Hematology.